Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children (COMIT1)

May 21, 2010 updated by: Menzies School of Health Research

Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.

This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo.

The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45.

Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

126

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Northern Territory
      • Darwin, Northern Territory, Australia, 0811
        • Menzies School of Health Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 1 year (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Australian Aboriginal
  • Living in participating remote community
  • Less than 12 months of age

Exclusion Criteria:

  • Less than 32 weeks gestation
  • Chronic condition requiring continuous antibiotic
  • Ear, nose or throat abnormality

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: 2
50 mg/kg/d twice daily
Active Comparator: 1
50 mg/kg/day twice daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of children with middle ear effusion
Time Frame: end of intervention
end of intervention
Proportion of study visits at which middle ear effusion detected
Time Frame: during intervention
during intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Proportion of infants with tympanic membrane perforation
Time Frame: end of intervention
end of intervention
Proportion of study visits with tympanic membrane perforation
Time Frame: during intervention
during intervention
Proportion of infants with nasopharyngeal colonisation with resistant Streptococcus pneumoniae
Time Frame: end of intervention
end of intervention
proportion of infants withdrawn from study due to intervention adverse events
Time Frame: end of intervention
end of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: John D Mathews, PhD, DSc., Menzies School of Health Research and University of Melbourne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 1996

Study Completion (Actual)

March 1, 2001

Study Registration Dates

First Submitted

October 2, 2007

First Submitted That Met QC Criteria

October 2, 2007

First Posted (Estimate)

October 4, 2007

Study Record Updates

Last Update Posted (Estimate)

May 24, 2010

Last Update Submitted That Met QC Criteria

May 21, 2010

Last Verified

October 1, 2007

More Information

Terms related to this study

Other Study ID Numbers

  • COMIT1
  • NHMRC 954086

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Otitis Media

Clinical Trials on Amoxycillin

Search Similar Trials